Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Corrigendum to "A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains" [Vaccine 37 (2019) 2369-2376].

Ross TM, DiNapoli J, Giel-Moloney M, Bloom CE, Bertran K, Balzli C, Strugnell T, Oomen RP, Sá E Silva M, Mebatsion T, Bublot M, Swayne DE, Kleanthous H.

Vaccine. 2019 Aug 2. pii: S0264-410X(19)30966-1. doi: 10.1016/j.vaccine.2019.07.058. [Epub ahead of print] No abstract available.

PMID:
31383487
2.

Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses.

Carlock MA, Ingram JG, Clutter EF, Cecil NC, Ramgopal M, Zimmerman RK, Warren W, Kleanthous H, Ross TM.

Hum Vaccin Immunother. 2019 Aug 8:1-14. doi: 10.1080/21645515.2019.1642056. [Epub ahead of print]

PMID:
31291153
3.

Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.

Cole LE, Li L, Jetley U, Zhang J, Pacheco K, Ma F, Zhang J, Mundle S, Yan Y, Barone L, Rogers C, Beltraminelli N, Quemeneur L, Kleanthous H, Anderson SF, Anosova NG.

Vaccine. 2019 Jun 27;37(29):3892-3901. doi: 10.1016/j.vaccine.2019.05.040. Epub 2019 May 20.

4.

A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains.

Ross TM, DiNapoli J, Giel-Moloney M, Bloom CE, Bertran K, Balzli C, Strugnell T, Sá E Silva M, Mebatsion T, Bublot M, Swayne DE, Kleanthous H.

Vaccine. 2019 Apr 17;37(17):2369-2376. doi: 10.1016/j.vaccine.2019.03.018. Epub 2019 Mar 21. Erratum in: Vaccine. 2019 Aug 2;:.

PMID:
30905528
5.

Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs.

Job ER, Ysenbaert T, Smet A, Christopoulou I, Strugnell T, Oloo EO, Oomen RP, Kleanthous H, Vogel TU, Saelens X.

NPJ Vaccines. 2018 Nov 29;3:55. doi: 10.1038/s41541-018-0093-1. eCollection 2018.

6.

Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.

Allen JD, Jang H, DiNapoli J, Kleanthous H, Ross TM.

J Virol. 2019 Jan 17;93(3). pii: e00946-18. doi: 10.1128/JVI.00946-18. Print 2019 Feb 1.

7.

Development of a Pan-H1 Influenza Vaccine.

Darricarrère N, Pougatcheva S, Duan X, Rudicell RS, Chou TH, DiNapoli J, Ross TM, Alefantis T, Vogel TU, Kleanthous H, Wei CJ, Nabel GJ.

J Virol. 2018 Oct 29;92(22). pii: e01349-18. doi: 10.1128/JVI.01349-18. Print 2018 Nov 15.

8.

Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine.

Giel-Moloney M, Goncalvez AP, Catalan J, Lecouturier V, Girerd-Chambaz Y, Diaz F, Maldonado-Arocho F, Gomila RC, Bernard MC, Oomen R, Delagrave S, Burdin N, Kleanthous H, Jackson N, Heinrichs J, Pugachev KV.

Sci Rep. 2018 Sep 4;8(1):13206. doi: 10.1038/s41598-018-31375-9.

9.

Effect of genetic background and delivery route on the preclinical properties of a live attenuated RSV vaccine.

Groppo R, DiNapoli J, Il Jeong K, Kishko M, Jackson N, Kleanthous H, Delagrave S, Zhang L, Parrington M.

PLoS One. 2018 Jun 19;13(6):e0199452. doi: 10.1371/journal.pone.0199452. eCollection 2018.

10.

Clinical and microbiological parameters of naturally occurring periodontitis in the non-human primate Macaca mulatta.

Colombo APV, Paster BJ, Grimaldi G, Lourenço TGB, Teva A, Campos-Neto A, McCluskey J, Kleanthous H, Van Dyke TE, Stashenko P.

J Oral Microbiol. 2017 Nov 25;9(1):1403843. doi: 10.1080/20002297.2017.1403843. eCollection 2017.

11.

A therapeutic Porphyromonas gingivalis gingipain vaccine induces neutralising IgG1 antibodies that protect against experimental periodontitis.

O'Brien-Simpson NM, Holden JA, Lenzo JC, Tan Y, Brammar GC, Walsh KA, Singleton W, Orth RKH, Slakeski N, Cross KJ, Darby IB, Becher D, Rowe T, Morelli AB, Hammet A, Nash A, Brown A, Ma B, Vingadassalom D, McCluskey J, Kleanthous H, Reynolds EC.

NPJ Vaccines. 2016 Dec 1;1:16022. doi: 10.1038/npjvaccines.2016.22. eCollection 2016.

12.

Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.

Job ER, Schotsaert M, Ibañez LI, Smet A, Ysenbaert T, Roose K, Dai M, de Haan CAM, Kleanthous H, Vogel TU, Saelens X.

J Virol. 2018 Jan 30;92(4). pii: e01584-17. doi: 10.1128/JVI.01584-17. Print 2018 Feb 15.

13.

Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains.

Nuñez IA, Carlock MA, Allen JD, Owino SO, Moehling KK, Nowalk P, Susick M, Diagle K, Sweeney K, Mundle S, Vogel TU, Delagrave S, Ramgopal M, Zimmerman RK, Kleanthous H, Ross TM.

PLoS One. 2017 Nov 1;12(11):e0185666. doi: 10.1371/journal.pone.0185666. eCollection 2017.

14.

A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses.

Shen C, Chen J, Li R, Zhang M, Wang G, Stegalkina S, Zhang L, Chen J, Cao J, Bi X, Anderson SF, Alefantis T, Zhang M, Cai X, Yang K, Zheng Q, Fang M, Yu H, Luo W, Zheng Z, Yuan Q, Zhang J, Wai-Kuo Shih J, Kleanthous H, Chen H, Chen Y, Xia N.

Sci Transl Med. 2017 Oct 18;9(412). pii: eaam5752. doi: 10.1126/scitranslmed.aam5752.

PMID:
29046433
15.

Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.

Wong TM, Allen JD, Bebin-Blackwell AG, Carter DM, Alefantis T, DiNapoli J, Kleanthous H, Ross TM.

J Virol. 2017 Nov 30;91(24). pii: e01581-17. doi: 10.1128/JVI.01581-17. Print 2017 Dec 15.

16.

Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.

Carter DM, Darby CA, Johnson SK, Carlock MA, Kirchenbaum GA, Allen JD, Vogel TU, Delagrave S, DiNapoli J, Kleanthous H, Ross TM.

J Virol. 2017 Nov 30;91(24). pii: e01283-17. doi: 10.1128/JVI.01283-17. Print 2017 Dec 15.

17.

Application of replication-defective West Nile virus vector to non-flavivirus vaccine targets.

Giel-Moloney M, Vaine M, Zhang L, Parrington M, Gajewska B, Vogel TU, Pougatcheva SO, Duan X, Farrell T, Ustyugova I, Phogat S, Kleanthous H, Pugachev KV.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2982-2986. doi: 10.1080/21645515.2017.1373920. Epub 2017 Sep 19.

18.

A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector.

Giel-Moloney M, Rumyantsev AA, David F, Figueiredo M, Feilmeier B, Mebatsion T, Parrington M, Kleanthous H, Pugachev KV.

Vaccine. 2017 Dec 14;35(49 Pt B):6898-6904. doi: 10.1016/j.vaccine.2017.08.055. Epub 2017 Sep 9.

PMID:
28899628
19.

Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.

Kalnin K, Chivukula S, Tibbitts T, Yan Y, Stegalkina S, Shen L, Cieszynski J, Costa V, Sabharwal R, Anderson SF, Christensen N, Jagu S, Roden RBS, Kleanthous H.

Vaccine. 2017 Sep 5;35(37):4942-4951. doi: 10.1016/j.vaccine.2017.07.086. Epub 2017 Aug 1.

20.

2016 International meeting of the Global Virus Network.

Akkina R, Ellerbrok H, Hall W, Hasegawa H, Kawaguchi Y, Kleanthous H, McSweegan E, Mercer N, Romanowski V, Sawa H, Vahlne A.

Antiviral Res. 2017 Jun;142:21-29. doi: 10.1016/j.antiviral.2017.03.005. Epub 2017 Mar 16.

PMID:
28315708
21.

Core bead chromatography for preparation of highly pure, infectious respiratory syncytial virus in the negative purification mode.

Mundle ST, Kishko M, Groppo R, DiNapoli J, Hamberger J, McNeil B, Kleanthous H, Parrington M, Zhang L, Anderson SF.

Vaccine. 2016 Jul 12;34(32):3690-6. doi: 10.1016/j.vaccine.2016.04.024. Epub 2016 May 26.

PMID:
27238375
22.

Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Carter DM, Darby CA, Lefoley BC, Crevar CJ, Alefantis T, Oomen R, Anderson SF, Strugnell T, Cortés-Garcia G, Vogel TU, Parrington M, Kleanthous H, Ross TM.

J Virol. 2016 Apr 14;90(9):4720-4734. doi: 10.1128/JVI.03152-15. Print 2016 May.

23.

Limitations of Murine Models for Assessment of Antibody-Mediated Therapies or Vaccine Candidates against Staphylococcus epidermidis Bloodstream Infection.

Cole LE, Zhang J, Kesselly A, Anosova NG, Lam H, Kleanthous H, Yethon JA.

Infect Immun. 2016 Mar 24;84(4):1143-1149. doi: 10.1128/IAI.01472-15. Print 2016 Apr.

24.

Prospects for treatment of Porphyromonas gingivalis-mediated disease - immune-based therapy.

Reynolds EC, O'Brien-Simpson N, Rowe T, Nash A, McCluskey J, Vingadassalom D, Kleanthous H.

J Oral Microbiol. 2015 Sep 18;7:29125. doi: 10.3402/jom.v7.29125. eCollection 2015.

25.

CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner.

Jeong KI, Piepenhagen PA, Kishko M, DiNapoli JM, Groppo RP, Zhang L, Almond J, Kleanthous H, Delagrave S, Parrington M.

PLoS One. 2015 Jun 24;10(6):e0130517. doi: 10.1371/journal.pone.0130517. eCollection 2015.

26.

A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.

Anosova NG, Cole LE, Li L, Zhang J, Brown AM, Mundle S, Zhang J, Ray S, Ma F, Garrone P, Bertraminelli N, Kleanthous H, Anderson SF.

Clin Vaccine Immunol. 2015 Jul;22(7):711-25. doi: 10.1128/CVI.00763-14. Epub 2015 Apr 29.

27.

Correction for Lam et al., antibodies to PhnD inhibit staphylococcal biofilms.

Lam H, Kesselly A, Stegalkina S, Charlebois RL, Oomen R, Kleanthous H, Yethon JA.

Infect Immun. 2015 May;83(5):2197. doi: 10.1128/IAI.00285-15. No abstract available.

28.

Preparation of pure, high titer, pseudoinfectious Flavivirus particles by hollow fiber tangential flow filtration and anion exchange chromatography.

Mundle ST, Giel-Moloney M, Kleanthous H, Pugachev KV, Anderson SF.

Vaccine. 2015 Aug 20;33(35):4255-60. doi: 10.1016/j.vaccine.2014.09.074. Epub 2014 Dec 9.

PMID:
25498209
29.

Antibodies to PhnD inhibit staphylococcal biofilms.

Lam H, Kesselly A, Stegalkina S, Kleanthous H, Yethon JA.

Infect Immun. 2014 Sep;82(9):3764-74. doi: 10.1128/IAI.02168-14. Epub 2014 Jun 23. Erratum in: Infect Immun. 2015 May;83(5):2197.

30.

Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.

Kalnin K, Tibbitts T, Yan Y, Stegalkina S, Shen L, Costa V, Sabharwal R, Anderson SF, Day PM, Christensen N, Schiller JT, Jagu S, Roden RB, Almond J, Kleanthous H.

Vaccine. 2014 Jun 12;32(28):3540-7. doi: 10.1016/j.vaccine.2014.04.032. Epub 2014 Apr 26.

31.

Single-dose vaccine against tick-borne encephalitis.

Rumyantsev AA, Goncalvez AP, Giel-Moloney M, Catalan J, Liu Y, Gao QS, Almond J, Kleanthous H, Pugachev KV.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13103-8. doi: 10.1073/pnas.1306245110. Epub 2013 Jul 15.

32.

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.

Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang HK, Chow LT, Huh WK, Jaganathan KS, Chivukula SV, Roden RB.

J Virol. 2013 Jun;87(11):6127-36. doi: 10.1128/JVI.03218-12. Epub 2013 Mar 27.

33.

Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.

Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Kleanthous H.

J Med Microbiol. 2013 Sep;62(Pt 9):1394-404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21.

PMID:
23518659
34.

High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo.

Mundle ST, Hernandez H, Hamberger J, Catalan J, Zhou C, Stegalkina S, Tiffany A, Kleanthous H, Delagrave S, Anderson SF.

PLoS One. 2013;8(2):e57224. doi: 10.1371/journal.pone.0057224. Epub 2013 Feb 26.

35.

Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.

Delagrave S, Hernandez H, Zhou C, Hamberger JF, Mundle ST, Catalan J, Baloglu S, Anderson SF, DiNapoli JM, Londoño-Hayes P, Parrington M, Almond J, Kleanthous H.

PLoS One. 2012;7(10):e46714. doi: 10.1371/journal.pone.0046714. Epub 2012 Oct 11.

36.

Characterization of the RepliVax platform for replication-defective flavivirus vaccines.

Rumyantsev AA, Giel-Moloney M, Liu Y, Gao QS, Zhang ZX, Catalan J, Frolov I, Almond J, Kleanthous H, Pugachev KV.

Vaccine. 2011 Jul 18;29(32):5184-94. doi: 10.1016/j.vaccine.2011.05.032. Epub 2011 May 26.

PMID:
21620917
37.

Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus.

Rumyantsev AA, Zhang ZX, Gao QS, Moretti N, Brown N, Kleanthous H, Delagrave S, Guirakhoo F, Collett MS, Pugachev KV.

Virology. 2010 Jan 20;396(2):329-38. doi: 10.1016/j.virol.2009.10.033. Epub 2009 Nov 12.

38.

Specific immunoglobulin A antibodies in maternal milk and delayed Helicobacter pylori colonization in Gambian infants.

Thomas JE, Bunn JE, Kleanthous H, Monath TP, Harding M, Coward WA, Weaver LT.

Clin Infect Dis. 2004 Oct 15;39(8):1155-60. Epub 2004 Sep 27.

PMID:
15486839
39.

Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen.

Londoño-Arcila P, Freeman D, Kleanthous H, O'Dowd AM, Lewis S, Turner AK, Rees EL, Tibbitts TJ, Greenwood J, Monath TP, Darsley MJ.

Infect Immun. 2002 Sep;70(9):5096-106.

40.

Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent.

Kleanthous H, Tibbitts TJ, Gray HL, Myers GA, Lee CK, Ermak TH, Monath TP.

Vaccine. 2001 Sep 14;19(32):4883-95.

PMID:
11535342
41.

Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones.

Sanchez V, Gimenez S, Haensler J, Geoffroy C, Rokbi B, Seguin D, Lissolo L, Harris B, Rizvi F, Kleanthous H, Monath T, Cadoz M, Guy B.

FEMS Immunol Med Microbiol. 2001 Mar;30(2):157-65.

42.

Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers.

DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL.

Vaccine. 1999 Oct 14;18(5-6):449-59.

PMID:
10519934
43.

Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori.

Lee CK, Soike K, Giannasca P, Hill J, Weltzin R, Kleanthous H, Blanchard J, Monath TP.

Vaccine. 1999 Aug 6;17(23-24):3072-82.

PMID:
10462242
44.

Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys.

Lee CK, Soike K, Hill J, Georgakopoulos K, Tibbitts T, Ingrassia J, Gray H, Boden J, Kleanthous H, Giannasca P, Ermak T, Weltzin R, Blanchard J, Monath TP.

Vaccine. 1999 Mar 17;17(11-12):1493-505.

PMID:
10195786
45.

Oral immunization with recombinant Helicobacter pylori urease confers long-lasting immunity against Helicobacter felis infection.

Myers GA, Ermak TH, Georgakopoulos K, Tibbitts T, Ingrassia J, Gray H, Kleanthous H, Lee CK, Monath TP.

Vaccine. 1999 Mar 17;17(11-12):1394-403.

PMID:
10195775
46.

Risk of Helicobacter pylori infection among long-term residents in developing countries.

Becker SI, Smalligan RD, Frame JD, Kleanthous H, Tibbitts TJ, Monath TP, Hyams KC.

Am J Trop Med Hyg. 1999 Feb;60(2):267-70.

PMID:
10072149
47.

Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses.

Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R, Lee CK, Kleanthous H, Monath TP.

J Exp Med. 1998 Dec 21;188(12):2277-88.

48.

Immunization against natural Helicobacter pylori infection in nonhuman primates.

Dubois A, Lee CK, Fiala N, Kleanthous H, Mehlman PT, Monath T.

Infect Immun. 1998 Sep;66(9):4340-6.

49.

Vaccine development against infection with Helicobacter pylori.

Kleanthous H, Lee CK, Monath TP.

Br Med Bull. 1998;54(1):229-41. Review.

PMID:
9604446
50.

Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection.

Kleanthous H, Myers GA, Georgakopoulos KM, Tibbitts TJ, Ingrassia JW, Gray HL, Ding R, Zhang ZZ, Lei W, Nichols R, Lee CK, Ermak TH, Monath TP.

Infect Immun. 1998 Jun;66(6):2879-86.

Supplemental Content

Loading ...
Support Center